588 results on '"Costa, Daniel B."'
Search Results
2. TIP60 is required for tumorigenesis in non‐small cell lung cancer
3. RSMA for Dual-Polarized Massive MIMO Networks: A SIC-Free Approach
4. Counteracting Eavesdropper Attacks Through Reconfigurable Intelligent Surfaces: A New Threat Model and Secrecy Rate Optimization
5. Rate-Splitting Multiple Access and its Interplay with Intelligent Reflecting Surfaces
6. EGFR Tyrosine Kinase Inhibitors for the Treatment of Metastatic Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Podcast
7. Targeting of drug-tolerant persister cells as an approach to counter drug resistance in non-small cell lung cancer
8. IRS-Assisted Massive MIMO-NOMA Networks with Polarization Diversity
9. Understanding UAV-Based WPCN-Aided Capabilities for Offshore Monitoring Applications
10. IRS-Assisted Massive MIMO-NOMA Networks: Exploiting Wave Polarization
11. What Role Do Intelligent Reflecting Surfaces Play in Multi-Antenna Non-Orthogonal Multiple Access?
12. Safeguarding MIMO Communications with Reconfigurable Metasurfaces and Artificial Noise
13. Activity and Safety of Mobocertinib (TAK-788) in Previously Treated Non–Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations from a Phase I/II Trial
14. Disparities in outcomes between Black and White patients in North America with thoracic malignancies and COVID-19 infection (TERAVOLT)
15. Correction to: EGFR Tyrosine Kinase Inhibitors for the Treatment of Metastatic Non‑Small Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Podcast
16. Analysis and Optimization of Tail-Biting Spatially Coupled Protograph LDPC Codes for BICM-ID Systems
17. EGFR exon 19 insertion EGFR-K745_E746insIPVAIK and others with rare XPVAIK amino-acid insertions: Preclinical and clinical characterization of the favorable therapeutic window to all classes of approved EGFR kinase inhibitors
18. On the Sum of Fisher-Snedecor F Variates and its Application to Maximal-Ratio Combining
19. Correction to: EGFR Tyrosine Kinase Inhibitors for the Treatment of Metastatic Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Podcast
20. Comparative genomic and immunopathologic analysis of lung adenocarcinomas with and without cytology‐proven malignant pleural effusions.
21. Multihop Weibull-fading communications: Performance analysis framework and applications
22. On Multihop Weibull-Fading Communications: Performance Analysis Framework and Applications
23. Association of Extended Dosing Intervals or Delays in Pembrolizumab-based Regimens With Survival Outcomes in Advanced Non–small-cell Lung Cancer
24. An Effective Simultaneous Channel Estimation and Sensing Algorithm for mmWave MIMO-OFDM Systems
25. Tensor-Based Joint Symbol Detection, User Localization and Tracking for THz Systems With Dual-Wideband Effects
26. Cooperative Spectrum Sharing Relaying Protocols With Energy Harvesting Cognitive User
27. User-Pairing Scheme in NOMA Systems: A PSO-Based Approach
28. Heart Failure Associated With the Epidermal Growth Factor Receptor Inhibitor Osimertinib
29. Association between immune-related adverse events and clinical outcomes to PD-1/PD-L1 blockade in small cell lung cancer
30. A Real-World Study of Patient Characteristics and Clinical Outcomes in EGFR Mutated Lung Cancer Treated with First-Line Osimertinib: Expanding the FLAURA Trial Results into Routine Clinical Practice
31. Autoencoder Based End-to-end OTFS System Design With Hardware Impairments
32. Durable Clinical Response to Entrectinib in NTRK1-Rearranged Non-Small Cell Lung Cancer
33. The impact of on-target resistance mediated by EGFR-T790M or EGFR-C797S on EGFR exon 20 insertion mutation active tyrosine kinase inhibitors
34. PD-L1 testing using the clone 22C3 pharmDx kit for selection of patients with non–small cell lung cancer to receive immune checkpoint inhibitor therapy: are cytology cell blocks a viable option?
35. miR-147b-mediated TCA cycle dysfunction and pseudohypoxia initiate drug tolerance to EGFR inhibitors in lung adenocarcinoma
36. Randomized Phase II Study of 3 Months or 2 Years of Adjuvant Afatinib in Patients With Surgically Resected Stage I-III EGFR-Mutant Non–Small-Cell Lung Cancer
37. Data from Activity and Safety of Mobocertinib (TAK-788) in Previously Treated Non–Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations from a Phase I/II Trial
38. Supplementary Data from Activity and Safety of Mobocertinib (TAK-788) in Previously Treated Non–Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations from a Phase I/II Trial
39. EGFR exon 20 insertion mutations and ERBB2 mutations in lung cancer: a narrative review on approved targeted therapies from oral kinase inhibitors to antibody-drug conjugates
40. “Rounding” the Size of Pulmonary Nodules: Impact of Rounding Methods on Nodule Management, as Defined by the 2017 Fleischner Society Guidelines
41. Molecular Testing Turnaround Time for Non–Small Cell Lung Cancer in Routine Clinical Practice Confirms Feasibility of CAP/IASLC/AMP Guideline Recommendations: A Single-center Analysis
42. Scientific Advances in Thoracic Oncology 2016
43. Lung Adenocarcinoma Manifesting as Pure Ground-Glass Nodules: Correlating CT Size, Volume, Density, and Roundness with Histopathologic Invasion and Size
44. Size Measurement and T-staging of Lung Adenocarcinomas Manifesting as Solid Nodules ≤30 mm on CT: Radiology-Pathology Correlation
45. The Impact of On-Target Resistance Mediated by EGFR-T790M or EGFR-C797S on EGFR Exon 20 Insertion Mutation Active Tyrosine Kinase Inhibitors
46. Data from TAS6417/CLN-081 Is a Pan-Mutation–Selective EGFR Tyrosine Kinase Inhibitor with a Broad Spectrum of Preclinical Activity against Clinically Relevant EGFR Mutations
47. Tables S1-3 and Figures S1-4 from TAS6417/CLN-081 Is a Pan-Mutation–Selective EGFR Tyrosine Kinase Inhibitor with a Broad Spectrum of Preclinical Activity against Clinically Relevant EGFR Mutations
48. EGFR Testing in Advanced Non–Small-Cell Lung Cancer, A Mini-Review
49. Targeted Biological Agents and Mechanisms
50. Supplementary Table and Figure Legends from EGFR Exon 20 Insertion Mutations Display Sensitivity to Hsp90 Inhibition in Preclinical Models and Lung Adenocarcinomas
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.